Inovio Amends Chinese Deal for Immunotherapy, Shares Up – Zacks.com
Zacks.com |
Inovio Amends Chinese Deal for Immunotherapy, Shares Up
Zacks.com Per the amended agreement, ApolloBio will have the exclusive right to develop and commercialize Inovio's DNA immunotherapy product, VGX-3100, within Greater China (China, Hong Kong, Macao, Taiwan). Currently, VGX-3100, which is an investigational … Inovio grabs $23M through HPV immunotherapy licensing deal with China's ApolloBio Inovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in … Could Inovio Pharmaceuticals, Inc. (INO) Rise Even More? The Stock Had Another Big Increase Today |
